HealthLinx and Cryptome embark on a future together
21 February, 2006 by Ruth BeranThe first merger of 2006 has created new opportunities in the hot field of theranostics. Ruth Beran talks with its architects about the merged company and its future plans.
Zenyth, MuriGen collaborate on inflammation targets
20 February, 2006 by Ruth BeranZenyth Therapeutics (ASX:ZTL), formerly Amrad, and unlisted Walter and Eliza Hall Institute (WEHI) spinout MuriGen Therapeutics are to co-develop a new class of drugs that target arthritis and other inflammatory diseases.
Oncomere discoveries open new avenues in cancer research
20 February, 2006 by Graeme O'NeillThe junk DNA revolution has thrown up yet another neologism for cancer geneticists to add to their spellcheckers: 'oncomere'.
QIMR scientists to trial malaria vaccine
16 February, 2006 by Ruth BeranScientists at the Queensland Institute of Medical Research (QIMR) are planning to commence a phase I clinical trial in Brisbane for a new malaria vaccine starting late this year or early next year.
Phylogica tech reviewed in journal
13 February, 2006 by Helen SchullerA review of Perth-based Phylogica's (ASX:PYC) Phylomer technology has been published in the February issue of Nature Biotechnology.
BrainZ expands US operations
10 February, 2006 by Helen SchullerAuckland-based BrainZ (ASX:BZI) has established its US clinical support team and headquarters.
DotScan helps join the dots in identifying heart disease
09 February, 2006 by Graeme O'NeillUniversity of Sydney researchers claim to have achieved almost perfect discrimination between two major forms of heart disease from patients' blood samples, using Sydney firm Medsaic's proprietary DotScan technology.
Prana completes Alzheimer's phase I
07 February, 2006 by Helen SchullerMelbourne's Prana Biotechnology (ASX:PBT, Nasdaq:PRAN) has successfully completed a second phase I trial of its lead compound PBT2, under development as a therapy for Alzheimer's disease.
Reshaped Australian healthcare firms hold promise
06 February, 2006 by Sonali PaulMost of Australia's leading healthcare firms are expected to post strong first-half profit growth and provide positive outlook statements as the benefits of takeovers and spin-offs start to filter through, according to analysts.
UQ team links vitamin D deficiency with schizophrenia, MS
06 February, 2006 by Graeme O'NeillScientists at the University of Queensland have linked maternal vitamin D deficiency in pregnancy to abnormal foetal brain development and an increased the risk of behavioural problems, schizophrenia and multiple sclerosis (MS) later in life.
CyGenics joins international cancer collaboration
03 February, 2006 by Helen SchullerCell therapy company CyGenics (ASX:CYN) will be part of a new international collaborative effort to develop new treatments of cancer using the novel approach of developing and mobilising immune cells outside the human body.
Prima publishes cancer trial results, outlines road ahead
02 February, 2006 by Helen SchullerPrima Biomed's (ASX:PRR) results from a phase I clinical trial of its CancerVac MFP technology for advanced adenocarcinoma have been accepted and published in the journal Clinical Cancer Research.
Giaconda touts results for H. Pylori, Crohn's disease
31 January, 2006 by Helen SchullerSydney-based Giaconda (ASX:GIA) has reported positive results from phase II trials of two of its compounds, Heliconda for Helicobacter pylori infection and Myoconda for Crohn's disease.
Benitec delays HIV/AIDS drug IND filing
31 January, 2006 by Ruth BeranGene therapy company Benitec's (ASX:BLT) shares fell on news that the US FDA investigational new drug (IND) filing for its HIV/AIDS therapeutic will be delayed.
Zenyth licence to boost antibody targets
30 January, 2006 by Graeme O'NeillZenyth Therapeutics (ASX:ZTL), formerly Amrad, has taken a licence from Massachusetts-based Dyax Corp, to use the US company's proprietary phage display libraries to develop antibody therapeutics for inflammation and cancer.
